Processing

Please wait...

Settings

Settings

Goto Application

1. WO2022160065 - FORMULATIONS INCLUDING DIHYDROHONOKIOL

Publication Number WO/2022/160065
Publication Date 04.08.2022
International Application No. PCT/CA2022/050134
International Filing Date 31.01.2022
IPC
A61K 31/05 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
05Phenols
A61P 25/30 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
30for treating abuse or dependence
C07C 39/23 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
CACYCLIC OR CARBOCYCLIC COMPOUNDS
39Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
23polycyclic, containing six-membered aromatic rings and other rings, with unsaturation outside the aromatic rings
Applicants
  • BETTERLIFE PHARMA INC. [CA]/[CA]
Inventors
  • KIRKLAND, Justin
  • KROUPA, Patrick
Agents
  • BARTOSZEWICZ, Lola A.
  • MCMANUS, Kimberly A.
  • SINDEN, William K.
  • REECE, Pia-Lauren
  • LOWTHERS, Erica L.
  • SABETA, Anton C.
  • MILLMAN, Jay M.
  • HUNDAL, Steve S.
Priority Data
63/143,86531.01.2021US
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) FORMULATIONS INCLUDING DIHYDROHONOKIOL
(FR) FORMULATIONS COMPRENANT DU DIHYDROHONOKIOL
Abstract
(EN) Disclosed herein are compositions, methods and uses for treating a sedative, hypnotic, or anxiolytic use disorder and related disorders. In some embodiments, the compositions comprise dihydrohonokiol-B ("DHH-B") and at least one pharmaceutically acceptable carrier, wherein the DHH-B is present in an amount ranging from between about 0.5% to about 25% by total weight of the composition. In other embodiments, the compositions comprise dihydrohonokiol-B ("DHH-B") and at least one pharmaceutically acceptable carrier, wherein the DHH-B is present in an amount ranging from between about 0.000001% to about 5% by total weight of the composition.
(FR) Des compositions, des procédés et des utilisations pour traiter un trouble de la consommations de sédatifs, d'hypnotiques ou d'anxiolytiques et des troubles apparentés. sont divulgués dans la présente invention. Dans certains modes de réalisation, les compositions comprennent du dihydrohonokiol-B (« DHH-B ») et au moins un support pharmaceutiquement acceptable, le DHH-B étant présent en une quantité allant d'environ 0,5 % à environ 25 % en poids total de la composition. Dans d'autres modes de réalisation, les compositions comprennent du dihydrohonokiol-B (« DHH-B ») et au moins un support pharmaceutiquement acceptable, le DHH-B étant présent en une quantité allant d'environ 0,000001 % à environ 5 % en poids total de la composition.
Latest bibliographic data on file with the International Bureau